PTD-SMAD7 therapeutics
The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
1. A protein molecule comprising a protein transduction domain and a human mothers against decapentaplegic-7 protein (Smad7) fragment comprising amino acids 203-258 of the human Smad7 protein, wherein the Smad7 fragment retains one or more biological activities of the functional full-length Smad7 protein, and with the proviso that the protein molecule lacks at least amino acids 1 to 25 of the human Smad7 protein.
2. The protein molecule of claim 1 , wherein the protein molecule has one or more biological activities selected from the group consisting of promoting wound healing, and treating inflammatory and auto-immune diseases and auto-immune disorders.
3. The protein molecule of claim 2 , wherein the protein molecule has one or more biological activities selected from the group consisting of promoting healing in oral mucositis, ulcers, diabetic wounds, and radiation-induced damage; reducing scarring and fibrosis; and treating psoriasis and inflammatory disorders.
4. The protein molecule of claim 1 , wherein the protein transduction domain is Tat.
5. The protein molecule of claim 1 , wherein the protein molecule comprises amino acids 203-426 of the human Smad7 protein.
6. The protein molecule of claim 5 , wherein the protein molecule has one or more biological activities selected from the group consisting of promoting wound healing, and treating inflammatory and auto-immune diseases and auto-immune disorders.
7. The protein molecule of claim 5 , wherein the protein molecule has one or more biological activities selected from the group consisting of promoting healing in oral mucositis, ulcers, diabetic wounds, and radiation-induced damage; reducing scarring and fibrosis; and treating psoriasis and inflammatory disorders.
8. The protein molecule of claim 5 , wherein the protein transduction domain is Tat.
9. A pharmaceutical composition comprising the protein molecule of claim 1 , and one or more pharmaceutically acceptable excipients.
10. A pharmaceutical composition comprising the protein molecule of claim 5 , and one or more pharmaceutically acceptable excipients.
11. A protein molecule comprising a protein transduction domain and a human mothers against decapentaplegic-7 protein (Smad7) fragment comprising amino acids 203-217 of the human Smad7 protein, wherein the Smad7 fragment retains one or more biological activities of the functional full-length Smad7 protein, and with the proviso that the protein molecule lacks at least amino acids 1 to 25 of the human Smad7 protein.
12. The protein molecule of claim 11 , wherein the protein transduction domain is Tat.
13. The protein molecule of claim 11 , wherein the protein molecule has one or more biological activity selected from the group consisting of promoting wound healing, and treating inflammatory and auto-immune diseases and auto-immune disorders.
14. The protein molecule of claim 13 , wherein the protein molecule has one or more biological activities selected from the group consisting of promoting healing in oral mucositis, ulcers, diabetic wounds, and radiation-induced damage; reducing scarring and fibrosis; and treating psoriasis and inflammatory disorders.
15. A pharmaceutical composition comprising the protein molecule of claim 11 , and one or more pharmaceutically acceptable excipients.
16. A protein molecule comprising a protein transduction domain and a human mothers against decapentaplegic-7 protein (Smad7) fragment consisting of amino acids 203-258 of the human Smad7 protein.
17. The protein molecule of claim 16 , wherein the protein molecule has one or more biological activities selected from the group consisting of promoting wound healing, and treating inflammatory and auto-immune diseases and auto-immune disorders.
18. The protein molecule of claim 17 , wherein the protein molecule has one or more biological activities selected from the group consisting of promoting healing in oral mucositis, ulcers, diabetic wounds, and radiation-induced damage; reducing scarring and fibrosis; and treating psoriasis and inflammatory disorders.
19. The protein molecule of claim 16 , wherein the protein transduction domain is Tat.
20. A pharmaceutical composition comprising the protein molecule of claim 16 , and one or more pharmaceutically acceptable excipients.
21. A protein molecule comprising a protein transduction domain and a human mothers against decapentaplegic-7 protein (Smad7) fragment consisting of amino acids 203-217 of the human Smad7 protein.
22. The protein molecule of claim 21 , wherein the protein molecule has one or more biological activities selected from the group consisting of promoting wound healing, and treating inflammatory and auto-immune diseases and auto-immune disorders.
23. The protein molecule of claim 22 , wherein the protein molecule has one or more biological activities selected from the group consisting of promoting healing in oral mucositis, ulcers, diabetic wounds, and radiation-induced damage; reducing scarring and fibrosis; and treating psoriasis and inflammatory disorders.
24. The protein molecule of claim 21 , wherein the protein transduction domain is Tat.
25. A pharmaceutical composition comprising the protein molecule of claim 21 , and one or more pharmaceutically acceptable excipients.
26. A protein molecule comprising a protein transduction domain and a human mothers against decapentaplegic-7 protein (Smad7) fragment consisting of amino acids 203-426 of the human Smad7 protein, wherein the Smad7 fragment retains one or more biological activities of the functional full-length Smad7 protein.
27. A method for treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the protein molecule of claim 11 .
28. A method for treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the protein of claim 11 , wherein the administration of the protein results in an increase in one or more of cell proliferation or cell migration, or reducing one or more of apoptosis or DNA damage in the subject.
29. A method for treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 9 .
30. A method for treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 9 , wherein the administration of the protein results in an increase in one or more of cell proliferation or cell migration, or reducing one or more of apoptosis or DNA damage in the subject.
31. A method for treating an inflammatory condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 15 .
32. A method for treating a disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 15 , wherein the administration of the protein results in an increase in one or more of cell proliferation or cell migration, or reducing one or more of apoptosis or DNA damage in the subject.